A5064021599- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Skin Protection and Aging
- Glioma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Brain Metastases and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Dermatologic Treatments and Research
- melanin and skin pigmentation
- Multiple and Secondary Primary Cancers
- Plant Pathogens and Resistance
- Chemotherapy-related skin toxicity
- Nutrition, Genetics, and Disease
- T-cell and Retrovirus Studies
- Natural Products and Biological Research
- Myasthenia Gravis and Thymoma
- Cutaneous lymphoproliferative disorders research
- Acne and Rosacea Treatments and Effects
- BRCA gene mutations in cancer
- Management Systems and Quality Improvement
- Retinoids in leukemia and cellular processes
The Maria Sklodowska-Curie National Research Institute of Oncology
2013-2023
Sapienza University of Rome
2002-2023
Laboratorium Kosmetyczne Dr Irena Eris (Poland)
2016-2019
Centrum Onkologii
2005-2012
Uczelnia Warszawska im. Marii Skłodowskiej-Curie
2012
Primary central nervous system lymphoma (PCNSL) is a rare, highly aggressive, extranodal form of non-Hodgkin lymphoma, predominantly diagnosed as primary diffuse large B-cell the (CNS DLBCL). Fast and precise diagnosis PCNSL critical yet challenging. microRNAs, important regulators in physiology pathology are potential biomarkers. In 131 patients with CNS DLBCL non-malignant brain lesions (n-ML), miR-21, miR-19b miR-92a, miR-155, miR-196b, miR-let-7b, miR-125b, miR-9 were examined by RT-qPCR...
Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85-95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results treatment 124 patients with PMBL over a period between 2004 and 2017 the use protocol designed for aggressive GMALL/B-ALL/NHL2002 including 6 cycles alternating immunochemotherapy intermediate-dose methotrexate each cycle, reduced total doxorubicin dose (100 mg/m2...
Clinical data on primary central nervous system (CNS) lymphoma (PCNSL) patients is mostly generated from prospective studies, and many frail real-world are not included. Recently,the diagnosis treatment of PCNSL was confounded by the COVID-19 pandemic. In particular, with high-dose cytarabine linked to increased risk pneumonia virus persistence. We report outcome induction regimen R-MIV (rituximab, methotrexate, ifosfamide, vincristine) involving intensive administration methotrexate (3.5...
(1) Background: T-cell lymphoblastic lymphoma (T-LBL) is extremely rare and highly aggressive, with no practical risk model defined yet. The prognostic value of T-LBL immunological subtypes still a matter controversy. (2) Methods: We re-evaluated 49 subsequent adult patients treated according to the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) protocols, 05/93 (n = 20) 1/2004 29), 85.7% which achieved complete remission (CR). (3) Results: 5/10-year overall...
Hyperpigmentation can be caused by long-term UV (ultraviolet) exposure, hormonal imbalances, skin ageing processes, as well inflammation, injuries and accumulation of hemosiderin.A brightening complex consisting niacin, Rumex spp.and biomimetic peptide is supposed to an efficient alternative for commonly used agents.In-vivo research night cream (1474) was conducted in order confirm the safety efficiency tri-active treatment facial hyperpigmentation.The on a group 30 female patients, applied...
The article presents the characteristics of Sector Qualification Map for IT prepared by Polish Society as part project “Development Maps based on Framework (divided into 2 parts)”. Reference number: IBE / 06/2020. It is to be one possibilities practical use Sectoral Qualifications in order better manage qualifications a given sector. Final Report completed project.
e18534 Background: Rituximab is part of nearly all protocols for treatment B-cell lymphoma and long infusion time demanded by the product monograph has created a burden busy hemato-oncology units limited number patients who may receive on time. Looking solution we performed an exploratory non-randomized study to evaluate safety rapid as described Sehn et al (Blood 2007). Methods: Between January December 2008, 125 with CD20+ lymphoma: DLBCL n= 80, BL n=6, FL n=22, MZL n=11, MCL n=4, CLL n=2,...
Diagnosis of high grade B lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangement, HGBL, NOS according to 2016 update WHO classification or diagnosis CD5+ diffuse large cell (DLBCL) results in poor prognosis an increased risk death progression compared other DLBCLsubtypes after RCHOP treatment. Here, we evaluated R-DAEPOCH regimen (rituximab dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) as a first-line treatment for patients aggressive B-cell autologous...
19506 Background: Optimal therapy of primary mediastinal B-cell lymphoma (PMBCL), a subtype diffuse large lymphoma, is matter debate. Methods: This retrospective analysis involving all PMBCL patients (n=68) treated at the Institute in Warsaw between 1992 and 2006. Initially, 42 pts (62%) were with CHOP, 2 MACOP-B, 4 CODOX-M/IVAC regimen (GM Mead et al. Ann Oncol 2002; 13: 1264) - without rituximab. Starting 2004, (n=20, 29%) entered into German Multicenter Study Group for ALL (GMALL)...
The efficacy of salvage treatment diffuse large B-cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety ofatumumab with iphosphamide, etoposide cytarabine (O-IVAC) was evaluated in a single-arm study. Dosing modified for elderly patients. Patients received up to six cycles treatment. primary end-point the overall response rate (ORR). were every two then 12 months Other end-points included progression-free survival (PFS),...
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal which associated with relatively poor prognosis compared to other diffuse large B-cell lymphomas. Population-based cancer registry data demonstrates that there has been significant improvement in the survival patients PCNSL over past two decades. This likely reflects introduction high-intensity chemotherapy based on an induction regimen high-dose methotrexate, and consolidation strategy including autologous stem...
e19525 Background: Median age of patients (pts) with diffuse large B cell lymphoma (DLBCL) is 65 years and the prevalence DLBCL in pts aged over 75 rapidly growing. In younger patients, standard induction RCHOP immunotherapy results about 70% cure. On other hand, older are frequently considered unfit for treatment, receive reduced doses doxorubicin or a drug substituted agents. Methods: Between 2007 2011, 69 (male - 35) year old were treated regimen two academic centers. Patient...